PriceTargets.com logo

Ocuphire Pharma - OCUP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: ∞
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$0.00 As of 10/23/2024 01:00 AM ET
+0 (0.00%)
Get New Ocuphire Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUP

Analyst Price Target is $16.00
▲ +∞ Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocuphire Pharma in the last 3 months. The average price target is $16.00, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for OCUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Ocuphire Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$18.00 ➝ $10.00
8/15/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $18.00
8/14/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
5/13/2024Canaccord Genuity GroupUpgradeStrong-Buy
5/13/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$22.00 ➝ $18.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
3/20/2024Alliance Global PartnersLower TargetBuy ➝ Buy$24.00 ➝ $20.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$17.00
3/31/2023HC WainwrightReiterated RatingBuy$20.00
2/17/2023HC WainwrightReiterated RatingBuy$20.00
1/26/2023HC WainwrightLower TargetBuy$26.00 ➝ $20.00
11/9/2022Canaccord Genuity GroupLower Target$29.00 ➝ $22.00
5/20/2022HC WainwrightReiterated RatingBuy$26.00
3/25/2022HC WainwrightReiterated RatingBuy$26.00
11/24/2021HC WainwrightInitiated CoverageBuy$26.00
4/5/2021Alliance Global PartnersInitiated CoverageBuy$25.00
3/29/2021JonestradingInitiated CoverageBuy$20.00
3/15/2021Cantor FitzgeraldBoost TargetOverweight ➝ Positive$15.00 ➝ $20.00
11/19/2020Cantor FitzgeraldInitiated CoverageOverweight$15.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ocuphire Pharma logo
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.26
Low: $1.17
High: $1.46

52 Week Range

Now: N/A

Volume

676,700 shs

Average Volume

171,840 shs

Market Capitalization

$30.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocuphire Pharma?

The following equities research analysts have issued reports on Ocuphire Pharma in the last twelve months: Alliance Global Partners, Canaccord Genuity Group Inc., and HC Wainwright.
View the latest analyst ratings for OCUP.

What is the current price target for Ocuphire Pharma?

0 Wall Street analysts have set twelve-month price targets for Ocuphire Pharma in the last year. Their average twelve-month price target is $16.00. Alliance Global Partners has the highest price target set, predicting OCUP will reach $20.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $10.00 for Ocuphire Pharma in the next year.
View the latest price targets for OCUP.

What is the current consensus analyst rating for Ocuphire Pharma?

Ocuphire Pharma currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUP will outperform the market and that investors should add to their positions of Ocuphire Pharma.
View the latest ratings for OCUP.

What other companies compete with Ocuphire Pharma?

Other companies that are similar to Ocuphire Pharma include Leap Therapeutics, Veru, Regulus Therapeutics, Journey Medical and BioHarvest Sciences. Learn More about companies similar to Ocuphire Pharma.

How do I contact Ocuphire Pharma's investor relations team?

Ocuphire Pharma's physical mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company's listed phone number is (248) 681-9815 and its investor relations email address is [email protected]. The official website for Ocuphire Pharma is www.ocuphire.com. Learn More about contacing Ocuphire Pharma investor relations.